FDA Advisory links Limbrel to potentially life-threatening health problems

The US Food and Drug Administration is investigating serious adverse events involving Limbrel (flavocoxid), a product in capsule form currently being marketed as a medical food to manage the metabolic processes associated with osteoarthritis, by Primus Pharmaceuticals.

While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis.